Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.45 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CETP | P11597 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | EPOR | P19235 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7535315 | 0.88 | EGFR (0.50) | EGFRHSD17B1HSD17B2MAPTALDH1A1 | |
| SCHEMBL26219078 | 0.83 | LIPE (0.60) | ALDH1A1POLBL3MBTL1 | |
| SCHEMBL28997016 | 0.77 | FFAR1 (0.44) | EGFRHSD17B1HSD17B2TLR7P2RY1 | |
| SCHEMBL29369580 | 0.77 | FFAR1 (0.44) | EGFRHSD17B1HSD17B2TLR7P2RY1 | |
| SCHEMBL22732030 | 0.74 | TGM2 (0.55) | EGFRMAPTALDH1A1 | |
| SCHEMBL5646595 | 0.74 | LIPE (0.64) | TLR7ALDH1A1L3MBTL1 | |
| SCHEMBL9798371 | 0.72 | LTA4H (0.54) | MAPTALDH1A1KDM4EPOLBL3MBTL1 | |
| SCHEMBL11756402 | 0.72 | BTK (0.46) | — | |
| SCHEMBL514284 | 0.72 | HSD17B1 (0.48) | HSD17B1HSD17B2MAPTALDH1A1POLB | |
| SCHEMBL24168417 | 0.71 | TLR8 (0.50) | TLR7TLR8P2RY1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286904-A1 | INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF | BRIDGENE BIOSCIENCES, INC. | 2023-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286904-A1 | INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF | TEAD1, TEAD2, TEAD3 | EGFR 342/4885HSD17B1 3906/4885HSD17B2 4450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.